TO AMEND THE LAW CONCERNING COVERAGE OF BIOSIMLAR MEDICAL PRODUCTS UNDER STEP THERAPY PROTOCOLS; AND TO AMEND EXCEPTIONS TO STEP THERAPY PROTOCOLS.
Bill status
signed
all 5 stages cleared
Introduction
Feb 2023
Committee Review
Feb 2023
Senate Passage
Feb 2023
House Passage
Feb 2023
Signed into Law
Feb 2023
Introduced Feb 1, 2023
Signed Feb 27, 2023
Floor votes · Senate Feb 8, 2023 · House Feb 16, 2023
How they voted
20–1
Passed
Total votes 21
Feb 8, 2023
D
Democratic2
100% Yea
R
Republican19
94% Yea
Vote distribution
All Yea
All Nay
Mixed
No data
Full legislative history
Actions timeline
Total actions
15
Key actions
7
Committee
2
Feb 27, 2023
Signed into law
Notification that SB192 is now Act 136
upper
Feb 16, 2023
Upper · Passed
Returned from the House as passed.
upper
Feb 16, 2023
Lower · Passed
Returned To the Senate as passed.
lower
Feb 16, 2023
Lower · Passed
Read the third time and passed and ordered transmitted to the Senate.
lower
Feb 15, 2023
Lower · Passed
Returned by the Committee Do Pass
lower
Feb 8, 2023
Upper · Passed
Read the third time and passed.
upper
Feb 7, 2023
Upper · Passed
Returned by the Committee, with the recommendation that it Do Pass
upper
Feb 1, 2023
Introduced
Filed
upper
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Brandon Achor
RRepublican
Ask Maddy
·
AI policy assistant
Ask Maddy about SB 192
Scope: AR
Hi! I can help you understand SB 192. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline